TGFB1 and familial pancreatic carcinoma: In this study, we found that treatment of vactosertib, a TGF-β signalling inhibitor, with either nal-IRI/5-FU/LV or nal-IRI significantly improved overall survival in a mouse model of pancreatic cancer by suppressing EMT and invasion of pancreatic cancer cells.